TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
In The News
2020 - 11 - 11
Merck announced on Nov. 7, 2020 that it is entering into a collaboration with Transcenta, a biotherapeutics company, to initiate continuous manufacturing for protein therapeutics.
According to a Transcenta press release, the companies will start off by developing and designing process technologies, single-use systems, and automation, with plans to eventually focus on an expanding process and digital technologies to optimize a continuous manufacturing process. The companies will also co-develop a single-use flow-through polishing system using Transcenta’s integrated continuous bioprocessing (ICB) Platform as part of the partnership.
Putting Biologics on the Fast Lane
Industrialization of Highly Intensified Connected/Continuous Biomanufacturing Platform (HiCB) to Address Patient and Business Needs
A CTO's Journey Into Continuous Biomanufacturing
TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors
BioPharm International：Moving Closer to End-to-End Continuous Bioprocessing
Merck Announces Collaboration with Transcenta for Continuous Manufacturing for Protein Therapeutics